SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News:
With reference to Chapter 4 Section 9 in ”lagen (1991:980) om handel med finansiella instrument” it’s hereby announced that through the subscription by a new share issue in Aerocrine the number of shares and votes in Aerocrine has increased during June 2014 as specified in the table below.
|Number of shares and votes|
|1-Jun-14||155 059 538|
|30-Jun-14||155 063 162|
|Solna June 30, 2014|
Aerocrine AB (publ.)
Aerocrine AB is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as Asthma. Within this sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® and NIOX VERO®, which enables fast and reliable point-of-care measurement of airway inflammation. These products plays a critical role in more effective diagnosis, treatment and follow-up of patients affected with inflammatory airway diseases. Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and www.niox.com.
Aerocrine may be required to disclose the information provided herein pursuant| |to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on June 30, 2014.
This information was brought to you by Cision http://news.cision.com